Literature DB >> 26149563

Roflumilast in COPD.

Erin Worndl1, Eoin B Hunt1, Marcus P Kennedy1, Michael T Henry1, Barry J Plant1, Desmond M Murphy2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26149563     DOI： 10.1378/chest.15-0664

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

Review 1.  Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.

Authors:  Swati Gulati; J Michael Wells
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

2.  Efficacy and safety profile of roflumilast in a real-world experience.

Authors:  Aykut Cilli; Halid Bal; Hakan Gunen
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

3.  Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease.

Authors:  Kyung Hoon Kim; Hye Seon Kang; Ju Sang Kim; Hyoung Kyu Yoon; Sung Kyoung Kim; Chin Kook Rhee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-04

4.  Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway.

Authors:  Wan Xu; Jingjing Zhang; Jing Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-07       Impact factor: 5.555
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.